QioMed

  • Determines GPCR structures plus initial agonists and antagonists in approximately three to six months, depending on the project and resources to be committed

  • Designs and implements validation and screening strategies

  • Designs ligands and leads that are highly specific to intended targets, reducing side effects

  • In partnered programs, provides expert biomedical insight and critical scientific expertise regarding the pathology and molecular pathways of disease

 

Contact us to discuss moving your program forward.